Factor IX Gene Therapy for Stable Hemophilic Arthropathy Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy approaches for hemophilia fail to establish long-term expression of the Factor, leading to irreversible hemophilic arthropathy due to peaks and troughs in coagulation factor activity levels, causing joint damage in hemophilia patients.
Innovation Solution
Utilizing a hyperactive variant of Factor IX (FIX-R338L) delivered via AAV vectors to achieve steady-state coagulation factor activity levels, minimizing joint damage by maintaining activity within a narrow range, preferably +/- 10% of the average, through gene therapy and/or protein replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regular protein replacement therapy is used to treat hemophilia, then coagulation factor activity is restored, but peaks and troughs in activity levels cause joint damage and hemophilic arthropathy
Solution Approach 1:
The patent replaces the mechanical/procedural system of regular protein infusion therapy with a biological gene therapy system. By introducing a functional copy of the Factor IX gene via AAV vector, the body's own cells continuously produce the coagulation factor, eliminating the need for external protein administration and the resulting activity fluctuations that cause joint damage.
Solution Approach 2:
The patent changes the fundamental parameter of coagulation factor delivery from intermittent exogenous protein administration to continuous endogenous production. This transforms the activity profile from peaked and troughed levels to stable, physiological levels, preventing the joint damage associated with activity fluctuations while maintaining adequate hemostasis.
2Duration of action of stationary object
If gene therapy is used to achieve long-term factor expression, then joint damage is prevented, but early attempts failed to establish long term expression
Solution Approach 1:
The patent uses an adeno-associated virus (AAV) vector as an intermediary carrier to deliver the Factor IX gene into patient cells. The AAV vector serves as a safe and effective mediator that enables long-term gene expression without the severe side effects of earlier gene therapy approaches, achieving both durability and reliability.
Solution Approach 2:
The patent improves upon failed gene therapy attempts by optimizing critical parameters including using self-complementary AAV vectors for enhanced expression, selecting appropriate promoters for sustained transcription, and implementing refined manufacturing processes. These parameter changes transform gene therapy from a failed experimental approach into a reliable, long-term treatment solution.
3Object-affected harmful factors
If hyperactive variant FIX-R338L is used to elevate activity levels, then joint damage is alleviated, but activity levels must be maintained within narrow range
Solution Approach 1:
The patent employs the body's own regulatory mechanisms to maintain Factor IX activity within the optimal range. The endogenous production system naturally responds to physiological needs, adjusting secretion rates to maintain homeostasis without external control, thereby achieving both joint protection and precise activity level management.
Solution Approach 2:
The patent leverages the body's inherent feedback control systems where coagulation factor levels are regulated through physiological feedback loops. When Factor IX levels rise, natural feedback mechanisms reduce further secretion, and when levels fall, secretion increases, automatically maintaining activity within the narrow range needed to prevent joint damage while avoiding thrombosis risk.
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The invention relates to a gene therapy vehicle for use in preventing, arresting and/or treating hemophilic arthropathy of a joint in a patient having hemophilia B, where the gene therapy vehicle comprises a nucleic acid that encodes a coagulation factor having Factor IX activity.